ReNeuron Holdings plc - Receives European Patent on Transplantation of Blood Cells into Brain

12-Aug-2002
ReNeuron Holdings plc announces that the European Patent Office ('EPO') has granted the Company's patent application on the use of haematopoietic cells for transplantation into the brain. The Company believes that this patent is of considerable importance given the increased commercial interest and recent scientific publication (1) on the use of stem and progenitor cells derived from blood or bone marrow to treat neurological diseases. The patent provides broad protection in the use of this technology to treat a wide variety of neurological diseases including Parkinson's disease, Huntington's disease, stroke and many others. On 7th May, ReNeuron announced that it had received notices of allowances for two key US patents relating to its immortalising genes and gene identification. Commenting on this latest grant, Dr Martin Edwards, Chief Executive of ReNeuron said; "ReNeuron is committed to developing stem cell therapies for the treatment of brain diseases. As outlined in our 2002 Annual Report issued last week, we are exploring several approaches to achieve this critically important goal. Much of our work uses stem cells derived directly from the brain but there may be alternative ways to generate cells suitable for transplantation into the brain that do not require working with embryonic or foetal cells as the starting point. "We believe that cells derived from blood or bone marrow represent the most attractive alternative approach and ReNeuron is naturally delighted to receive this patent with broad and potentially commercially important claims". 1. See Jiang Y et al, Nature 418, 4th July 2002.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances